Topics: SarcomaMedical OncologyGIST
How do you approach adjuvant therapy for a resected gastric GIST when the risk for recurrence is discordant between various prediction tools?  

For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria.  The same tumor would have met inclusion criteria for adjuvant therapy in EORTC trial but is not "high risk."

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at St Jude Heritage Medical Group
How about the "low risk" but a large gastric GIST,...
Sign in or Register to read more